Research and analysis highlights
The first regenerative cell therapies to generate significant market value (within the next five years) will be based on allogeneic adult cells, and will target tissues that are naturally sheltered from patients' immune systems.
Autologous cells are not rejected by the patient's immune system, so are potentially safer than allogeneic cells and more suitable for permanent tissue replacement. "High tech" therapies based on reprogrammed autologous cells (e.g. induced pluripotent stem cells) may still be 20 years from market.
Tissue engineering still faces technical hurdles, including vascularization of grafted tissue and safe breakdown of scaffold materials. Research and regulatory efforts must be coordinated internationally to develop a stronger "evidence base" for regenerative medicine that is accessible and acceptable to all stakeholders.
Key reasons to purchase this research
• What is regenerative medicine and why are so many companies and investors excited about it?
• Which companies are currently developing new regenerative treatments and what approaches are they pursuing?
• What partnerships have been formed to develop new therapies, and where are the opportunities for further deals?
• What will the next generation of regenerative medicine candidates look like, and which indications will they treat?
• What hurdles do these candidates face en route to the marketplace?
TABLE OF CONTENTS
About the author 2
Executive Summary 12
An introduction to regenerative medicine 12
Allogeneic regenerative cell therapies 12
Autologous regenerative cell therapies 13
Tissue engineering 14
Regenerative drug molecules 14
Regenerative devices and implants 15
The future of regenerative medicin
Copyright©2010 PR Newswire.
All rights reserved